IONS IONIS PHARMACEUTICALS INC
Pharmaceutical Preparations · Nasdaq · SEC CIK 874015 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY-0.7%
TTM net income YoY-113.2%
TTM EPS YoY-96.4%
Revenue 3-yr CAGR16.0%
Net income 3-yr CAGR—
Margins
Gross margin98.2%
Operating margin-58.8%
Net margin-56.9%
FCF margin-64.2%
EBITDA margin-57.4%
Returns
ROE-108.1%
ROA-18.4%
ROIC (approx.)-236.8%
Asset turnover0.32x
Leverage & solvency
Liabilities / assets86.5%
Debt / equity0.00x
Current ratio5.43x
Interest coverage-29.37x
Cash quality & payout
Operating cash flow / net income1.00x
Accruals ratio-0.1%
Payout ratio—
Capex / revenue7.5%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q42025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q42024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $242.72M | $267.95M | $246.09M | $203.33M | $156.72M | $452.05M | $131.61M | $226.58M |
| Cost of revenue | $3.32M | $2.74M | $2.98M | $7.96M | $2.34M | $4.15M | $1.46M | $3.83M |
| Gross profit | $239.40M | $265.21M | $243.11M | $195.37M | $154.38M | $447.90M | $130.15M | $222.75M |
| SG&A expense | $154.22M | $150.40M | $150.36M | $130.19M | $96.81M | $90.62M | $76.25M | $88.08M |
| Operating income | -$130.70M | -$102.29M | -$117.42M | -$214.46M | -$160.18M | $139.82M | -$146.86M | -$110.82M |
| Interest expense | $4.63M | $4.62M | $5.16M | $4.83M | $4.21M | $4.11M | $4.11M | $4.19M |
| Pretax income | -$110.11M | -$113.38M | -$92.31M | -$227.92M | -$128.39M | $123.53M | -$146.82M | -$107.04M |
| Income tax | -$141,000 | $1.26M | $218,000 | $1.48M | $213,000 | -$20,000 | $116,000 | -$2.69M |
| Net income | -$109.97M | -$114.65M | -$92.53M | -$229.39M | -$128.61M | $123.55M | -$146.94M | -$104.35M |
| EBITDA | -$127.10M | -$98.86M | -$114.12M | -$211.20M | -$157.93M | $142.08M | -$144.63M | -$108.58M |
| EPS (basic) | -0.66 | -0.69 | -0.56 | -1.41 | -0.80 | 0.78 | -0.93 | -0.66 |
| EPS (diluted) | -0.66 | -0.69 | -0.56 | -1.41 | -0.80 | 0.70 | -0.93 | -0.66 |
| Weighted avg. shares (diluted) | 166.21M | 165.42M | 164.87M | — | 159.76M | 182.33M | 158.74M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $296.30M | $350.06M | $173.38M | $372.26M | $338.34M | $297.30M | $264.19M | $242.08M |
| Short-term investments | $1.59B | $1.70B | $1.75B | $2.31B | $1.90B | $1.99B | $1.88B | $2.06B |
| Inventory | $28.58M | $50.83M | $5.56M | $10.05M | $10.47M | $8.48M | $11.50M | $12.51M |
| Current assets | $2.36B | $2.49B | $2.94B | $2.99B | $2.52B | $2.58B | $2.42B | $2.62B |
| PP&E, net | $162.06M | $155.13M | $142.40M | $123.05M | $106.12M | $111.95M | $102.92M | $94.25M |
| Total assets | $2.91B | $2.99B | $3.45B | $3.52B | $3.03B | $2.99B | $2.81B | $3.00B |
| Current liabilities | $435.29M | $315.64M | $716.59M | $781.57M | $903.46M | $897.24M | $250.29M | $309.32M |
| Short-term debt | — | — | — | $432.12M | — | — | — | $165,000 |
| Long-term debt | — | — | — | $1.33B | — | — | — | $1.20B |
| Total debt | — | — | — | $1.76B | — | — | — | $1.20B |
| Total liabilities | $2.52B | $2.55B | $2.96B | $3.03B | $2.42B | $2.35B | $2.34B | $2.42B |
| Shareholders' equity | $393.64M | $439.74M | $491.41M | $489.09M | $617.97M | $631.72M | $475.73M | $588.35M |
| Net debt | — | — | — | $1.39B | — | — | — | $960.49M |
| Shares outstanding | 166.41M | 165.64M | 165.90M | 163.30M | 161.14M | 159.20M | 159.04M | 157.91M |
| Cash flow statement | ||||||||
| Operating cash flow | -$179.42M | $565.53M | -$792.82M | -$137.71M | -$131.44M | $151.34M | -$150.78M | -$116.14M |
| Capital expenditure | $12.71M | $16.08M | $21.76M | $21.29M | $5.27M | $12.30M | $12.58M | $25.50M |
| Free cash flow | -$192.13M | $549.45M | -$814.58M | -$159.00M | -$136.71M | $139.03M | -$163.35M | -$141.64M |
| Investing cash flow | $99.88M | $23.50M | $536.82M | -$419.50M | $91.34M | -$120.07M | $170.46M | $68.21M |
| Financing cash flow | $25.79M | -$412.29M | $57.26M | $591.18M | $81.22M | $1.25M | $2.20M | -$44.12M |
| Depreciation & amortization | $3.60M | $3.43M | $3.30M | $3.26M | $2.25M | $2.27M | $2.23M | $2.24M |
| Stock-based compensation | $43.42M | $45.59M | $43.27M | $43.32M | $31.15M | $29.69M | $29.72M | $36.15M |
Free plan shows the latest 8 periods; Pro shows all 70 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.